ArticleJournal of gastrointestinal oncology2025
STRIP2 promotes hepatocellular carcinoma progression and immune evasion: a potential prognostic biomarker and therapeutic target.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulation of immune tolerance in hepatocellular carcinoma by liver diseases: a review.Infectious agents and cancer · 2026Review
- Prognostic stratification in hepatocellular carcinoma using a telomerase-related lncRNA signature derived from TCGA database.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: STRIP2 is a key regulator of cytoskeletal dynamics, yet its precise role in hepatocellular carcinoma (HCC) remains unclear. This study aimed to elucidate the mechanistic function of STRIP2 in HCC progression. Methods: STRIP2 expression was analyzed using public databases. The prognostic significance and predictive value of STRIP2 were assessed through Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curves, univariate and multivariate Cox regression, and nomogram models. Enrichment analysis was performed to explore STRIP2-related signaling pathways. Immune infiltration analysis was conducted to examine the relationship between STRIP2 and the tumor immune microenvironment. Tumor Immune Dysfunction and Exclusion (TIDE) scores and drug sensitivity analyses were used to evaluate the therapeutic relevance of STRIP2. Finally, immunohistochemistry (IHC) and immunofluorescence (IF) staining were performed to validate STRIP2 expression and its prognostic significance in a clinical cohort, while its functional role in HCC cells was investigated through knockout experiments. Results: STRIP2 expression was found to be significantly upregulated in HCC tissues based on public database analysis, enrichment and immune infiltration analyses indicated that high STRIP2 expression was linked to an immunosuppressive tumor microenvironment, characterized by increased Th2 cell infiltration and reduced CD8 Conclusions: STRIP2 functions as a tumor-promoting factor in HCC, facilitating tumor progression, immune evasion, and therapy resistance. STRIP2 may serve as a novel biomarker and a promising target for precision treatment in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.